Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC).
Jonathan W. Riess(University of California Davis Medical Center), Ezra E.W. Cohen(Moores Cancer Center), Shane O’Neill(Royal College of Surgeons in Ireland), Devraj Srinivasan(Edinburgh Cancer Research), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pilar Garrido(Hospital Universitario Ramón y Cajal), Alireza Alavi, Jacqueline Vuky(Oregon Health & Science University), E. Ehrnrooth(Boehringer Ingelheim (Germany)), Paul Shaw(Velindre Cancer Centre), Diane Opatt McDowell(GlaxoSmithKline (United States))
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k